Electrotransfer of IL-15/IL-15Rα Complex for the Treatment of Established Melanoma
Autor: | Shawna A. Shirley, Niculina I. Burcus, Richard Heller, Cathryn Lundberg |
---|---|
Rok vydání: | 2020 |
Předmět: |
IL15Rα
0301 basic medicine Cancer Research Genetic enhancement medicine.medical_treatment Immunology Cell Gene electrotransfer Bioinformatics lcsh:RC254-282 Article 03 medical and health sciences Immune system 0302 clinical medicine Plasmid dna melanoma medicine Immunology and Allergy Receptor Pharmacology biology business.industry Melanoma Immunotherapy Mouse Melanoma lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease gene therapy cytokines 030104 developmental biology medicine.anatomical_structure IL-15 Oncology Integrin alpha M Treated animal Interleukin 15 030220 oncology & carcinogenesis Poster Presentation Cancer research biology.protein Molecular Medicine immunotherapy business Function (biology) |
Zdroj: | Cancers Cancers, Vol 12, Iss 3072, p 3072 (2020) Journal for Immunotherapy of Cancer Volume 12 Issue 10 |
ISSN: | 2072-6694 |
DOI: | 10.3390/cancers12103072 |
Popis: | Gene electrotransfer (GET) is a safe, reliable, and effective method of delivering plasmid DNA (pDNA) to solid tumors. GET has been previously used to deliver interleukin-15 (IL-15) to mouse melanoma, resulting in long-term tumor regression and the survival of a percentage of treated animals after challenge. To enhance this effect, we evaluated modulating the expression levels of IL-15 and co-expressing its receptor, IL-15R&alpha GET was used to deliver plasmids encoding IL-15 and IL-15R&alpha to established B16.F10 tumors on days 0, 4, and 7. Two delivery protocols that yielded different expression profiles were utilized. Mice that were tumor-free for 50 days were then challenged with B16.F10 cells on the opposite flank and monitored for an additional 50 days. The amount of IL-15 expressed and the presence or absence of IL-15R&alpha in the treated tumors did not significantly affect the tumor regression and long-term survival. Upon challenge, however, low levels of IL-15 were more protective and resulted in a greater production of anti-tumor cytokines such as IFN-&gamma and MIP-1&beta and a greater amount of CD11b+ and CD3e+ cells infiltrating tumors. While mice with high levels of IL-15 showed CD11b+ and CD3e+ cell infiltrate, there was a substantial presence of NK cells that was absent in other treated groups. We can conclude that the level of IL-15 expressed in tumors after GET is an important determinant of the therapeutic outcome, a finding that will help us finetune this type of therapy. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |